Cargando…
A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases?
The safety, inherent immunogenicity, stability, and low-cost production of bacteriophages make them an ideal platform for vaccine development. Most vaccination strategies against COVID-19 have targeted the spike protein of SARS-CoV-2 to generate neutralizing antibodies. P1, a truncated RBD-derived s...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144462/ https://www.ncbi.nlm.nih.gov/pubmed/37112745 http://dx.doi.org/10.3390/vaccines11040833 |
_version_ | 1785034105732202496 |
---|---|
author | Salehi, Zahra Rasaee, Mohammad Javad |
author_facet | Salehi, Zahra Rasaee, Mohammad Javad |
author_sort | Salehi, Zahra |
collection | PubMed |
description | The safety, inherent immunogenicity, stability, and low-cost production of bacteriophages make them an ideal platform for vaccine development. Most vaccination strategies against COVID-19 have targeted the spike protein of SARS-CoV-2 to generate neutralizing antibodies. P1, a truncated RBD-derived spike protein, has been shown to induce virus-neutralizing antibodies in preclinical studies. In this study, we first investigated whether recombinant phages displaying P1 on the M13 major protein could immunize mice against COVID-19, and second, whether inoculation with 50 µg of purified P1 in addition to the recombinant phages would stimulate the immune systems of the animals. The results showed that the mice that received recombinant phages were immunized against the phage particles, but did not have anti-P1 IgG. In contrast, compared with the negative control, the group that received a combination of P1 protein and recombinant phage was immunized against the P1 protein. In both groups, CD4(+) and CD8(+) T cells appeared in the lung tissue. These results suggest that the number of antigens on the phage body plays a crucial role in stimulating the immune system against the bacteriophage, although it is immunogenic enough to function as a phage vaccine. |
format | Online Article Text |
id | pubmed-10144462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101444622023-04-29 A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases? Salehi, Zahra Rasaee, Mohammad Javad Vaccines (Basel) Article The safety, inherent immunogenicity, stability, and low-cost production of bacteriophages make them an ideal platform for vaccine development. Most vaccination strategies against COVID-19 have targeted the spike protein of SARS-CoV-2 to generate neutralizing antibodies. P1, a truncated RBD-derived spike protein, has been shown to induce virus-neutralizing antibodies in preclinical studies. In this study, we first investigated whether recombinant phages displaying P1 on the M13 major protein could immunize mice against COVID-19, and second, whether inoculation with 50 µg of purified P1 in addition to the recombinant phages would stimulate the immune systems of the animals. The results showed that the mice that received recombinant phages were immunized against the phage particles, but did not have anti-P1 IgG. In contrast, compared with the negative control, the group that received a combination of P1 protein and recombinant phage was immunized against the P1 protein. In both groups, CD4(+) and CD8(+) T cells appeared in the lung tissue. These results suggest that the number of antigens on the phage body plays a crucial role in stimulating the immune system against the bacteriophage, although it is immunogenic enough to function as a phage vaccine. MDPI 2023-04-13 /pmc/articles/PMC10144462/ /pubmed/37112745 http://dx.doi.org/10.3390/vaccines11040833 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Salehi, Zahra Rasaee, Mohammad Javad A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases? |
title | A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases? |
title_full | A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases? |
title_fullStr | A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases? |
title_full_unstemmed | A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases? |
title_short | A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases? |
title_sort | recombinant rbd-based phage vaccine report: a solution to the prevention of new diseases? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144462/ https://www.ncbi.nlm.nih.gov/pubmed/37112745 http://dx.doi.org/10.3390/vaccines11040833 |
work_keys_str_mv | AT salehizahra arecombinantrbdbasedphagevaccinereportasolutiontothepreventionofnewdiseases AT rasaeemohammadjavad arecombinantrbdbasedphagevaccinereportasolutiontothepreventionofnewdiseases AT salehizahra recombinantrbdbasedphagevaccinereportasolutiontothepreventionofnewdiseases AT rasaeemohammadjavad recombinantrbdbasedphagevaccinereportasolutiontothepreventionofnewdiseases |